Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors propping up new companies to further develop assets …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Clinical-stage CDMOs should expect a rise in demand in 2024 as funding for early-stage biopharma stabilizes and biotechs may shed their in-house manufacturing to save
An anticipated reduction in biotech sales contributed to Danaher’s third-quarter performance dropping relative to last year, the company revealed Tuesday. This is in the midst
CrowdStrike, a growing cybersecurity firm, unwittingly triggered a massive IT outage on Friday, disrupting businesses, including healthcare, after issuing what was supposed to be a routine software